Novo Nordisk A/S Sponsored ADR Class B Equity Research & Stock Reports

Equity Research, Broker Reports, and media content on Novo Nordisk A/S Sponsored ADR Class B

Access the latest forecasts, broker valuations, multiples, and video content from the city about Novo Nordisk A/S Sponsored ADR Class B
See live updates from analysts, company announcements, and other news in a personalised/single dashboard

07 Nov 24

Successful first step in 3-stage “turnaround”

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

06 Nov 24

A "relief quarter" with 23% sales growth

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

01 Nov 24

Q4 looks to be an inflection point for sentiment

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

08 Aug 24

Pricing worries appear overblown

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

07 Aug 24

Q2 0-2% below, but growth case intact

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

05 Aug 24

Heads-up for Q2 report 7 August

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

11 Jul 24

Wegovy growth reigniting guidance

Q2 report 7 on August, with high probability of a guidance upgrade. Wegovy Q2 supply and sales run-rate into H2'24 in focus. A strong stock with significant earnings growth and power. BUY.

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

03 May 24

Lower-quality 24% CER growth in Q1

Q1 with 24% CER growth and 9-10% EBIT beat. Growth to accelerate firmly in remainder of 2024. Reiterate BUY, but little sentiment help from Q1 report.

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

02 May 24

Strong Q1 numbers, boosted by Gross2Net

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

28 Apr 24

"Slow" Q1 with ONLY 22% CER growth

Companies: Novo Nordisk A/S Class B

ABG Sundal Collier

11 Mar 24

Are you not entertained?

CMD Day 2 a master class on Novo's LT sustainable supply edge. FDA approval for SELECT data on label, another long-term advantage. TP DKK 1100 (900) on 2024e P/E rolling ionto 2025e: BUY.

Companies: Novo Nordisk (NOVO-B:CPH)Novo Nordisk A/S Class B (NOVO.B:CSE)

ABG Sundal Collier

08 Mar 24

CMD Day 1 low in news, high in calorie content

Companies: Novo Nordisk (NOVO-B:CPH)Novo Nordisk A/S Class B (NOVO.B:CSE)

ABG Sundal Collier

05 Mar 24

CMD looking mostly positive

CMD 7 March at HQ in Denmark, Kalundborg site visit 8 March. Positive newsflow likely, supportive for obesity market size. Estimates and TP of DKK 900 unchanged as we await CMD.

Companies: Novo Nordisk (NOVO-B:CPH)Novo Nordisk A/S Class B (NOVO.B:CSE)

ABG Sundal Collier

05 Feb 24

De-risking, speeding up and problem solving

Companies: Novo Nordisk (NOVO-B:CPH)Novo Nordisk A/S Class B (NOVO.B:CSE)

ABG Sundal Collier

01 Feb 24

The numbers are mind-boggling

Strong Q4 with 43% sales and 66% EBIT growth. 2024 newsflow looks supportive for sentiment and the stock. EPS +3% and TP DKK 900 (860), BUY on obesity and earnings growth.

Companies: Novo Nordisk (NOVO-B:CPH)Novo Nordisk A/S Class B (NOVO.B:CSE)

ABG Sundal Collier